2015年风湿免疫病主要进展

doi:10.3969/j.issn.1004-583X.2016.02.006

临床荟萃 ›› 2016, Vol. 31 ›› Issue (2): 156-161.doi: 10.3969/j.issn.1004-583X.2016.02.006

2015年风湿免疫病主要进展

高丽霞,郭惠芳

河北医科大学第二医院免疫风湿科,河北石家庄 050000

收稿日期:2016-01-19 出版日期:2016-02-05 发布日期:2016-04-18
通讯作者: 郭惠芳,Email:guohfch@126.com
作者简介:高丽霞,女,河北医科大学第二医院风湿免疫科副主任医师,清华大学中国协和医科大学北京协和医院风湿病专业医学博士,硕士生导师。现任中华风湿病学会第九届青年委员,河北省免疫学会委员。长期从事风湿病学临床、科研和教学工作,曾在国内外专业杂志上发表SCI、核心期刊文章共30余篇,独立承担省级厅级科研项目5项,获省科技进步奖等科技成果奖3项。

Major clinical progress of rheumatic disease in 2015

Gao Lixia, Guo Huifang

Department of Immunology and Reumatology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China

Received:2016-01-19 Online:2016-02-05 Published:2016-04-18
Contact: Guo Huifang, Email:guohfch@126.com

摘要/Abstract

摘要： 2015年风湿病的临床进展主要集中在针对类风湿关节炎、风湿性多肌痛、IgG4相关性疾病和银屑病关节炎管理指南和治疗策略的改变,同时更新了原发性干燥综合征和痛风的诊断标准。国内则针对系统性红斑狼疮相关肺动脉高压给出了相应的指南,并对妊娠围产期的系统性红斑狼疮患者给出了我国的围产期管理建议。2015年不仅关注风湿病本身,同时关注了风湿病的共患病, 尤其心血管疾病等并发症,并且更加强调患者教育。

关键词: 风湿性疾病, 关节炎, 类风湿, 风湿性多肌痛, 痛风, 关节炎, 牛皮癣

Abstract: The clinical progress of rheumatic disease mainly concentrated in the change of management guidelines and treatment strategies in rheumatoid arthritis, rheumatic polymyalgia, IgG4 related disease and psoriasis arthritis during 2015. At the same time, the diagnostic criteria of primary Sjogren syndrome and gout were updated. The guidelines of systemic lupus erythematous (SLE) -associated pulmonary arterial hypertension were made, and our domestic rheumatologists made management suggestions for SLE patients during pregnancy and the puerperium. Both rheumatism itself and comorbidity attracted attention to in 2015, especially rheumatic diseases complicated with cardiovascular disease, and patient educations were more emphasized.

Key words: rheumatic diseases, arthritis,rheumatoid, rheumatic polymyalgia, gout, arthritis,psoriatic

中图分类号:

R593.21

高丽霞,郭惠芳. 2015年风湿免疫病主要进展[J]. 临床荟萃, 2016, 31(2): 156-161.

Gao Lixia, Guo Huifang. Major clinical progress of rheumatic disease in 2015[J]. Clinical Focus, 2016, 31(2): 156-161.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.02.006

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I2/156

参考文献

[1] Gibson DS, Bustard MJ, McGeough CM, et al. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis[J]. Expert Rev Mol Diagn, 2015,15(2):219-234.
[2] Breedveld F. TNF antagonists opened the way to personalized medicine in rheumatoid arthritis[J]. Mol Med ,2014,20(Suppl 1):S7-9.
[3] Huizinga TW. Personalized medicine in rheumatoid arthritis: is the glass half full or half empty? [J]J Intern Med, 2015,277(2):178-187.
[4] Woodworth TG, den Broeder AA. Treating to target in established rheumatoid arthritis: challenges and opportunities in an era of novel targeted therapies and biosimilars[J]. Best Pract Res Clin Rheumatol, 2015,29(4/5):543-549.
[5] Abasolo L, Leon L, Rodriguez-Rodriguez L, et al. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions[J]. Semin Arthritis Rheum, 2015,44(5):506-513.
[6] Barber CE, Smith A, Esdaile JM, et al. Best practices for cardiovascular disease prevention in rheumatoid arthritis: a systematic review of guideline recommendations and quality indicators[J]. Arthritis Care Res (Hoboken),2015,67(2):169-179.
[7] Ikdahl E, Rollefstad S, Olsen IC, et al. EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic[J]. Biomed Res Int, 2015,2015:515280.
[8] Mirabelli G, Cannarile F, Bruni C,et al. One year in review 2015: systemic lupus erythematosus[J]. Clin Exp Rheumatol, 2015,33(3):414-425.
[9] Willis R, Seif AM, McGwin G, et al. Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort[J]. Clin Exp Rheumatol, 2014,32(2):162-167.
[10] No authors. Abstracts of the 11th International Congress on Systemic Lupus Erythematosus, September 2-6, 2015, Vienna, Austria[J]. Clin Exp Rheumatol, 2015,33(3 Suppl 90):S3-S82.
[11] Strand V, Petri M, Kalunian K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006[J]. Rheumatology (Oxford),2014,53(3):502-511.
[12] Wang Z, Wang Y, Zhu R, et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies[J]. Medicine (Baltimore),2015,94(17):e794.
[13] 国家风湿病数据中心,中国系统性红斑狼疮研究协作组.中国成人系统性红斑狼疮相关肺动脉高压诊治共识[J].中华内科杂志,2015,54(1): 81-86.
[14] 中国系统性红斑狼疮研究协作组专家组国家风湿病数据中心.中国系统性红斑狼疮患者围产期管理建议[J]. 中华医学杂志,2015,95(14)1050-1060.
[15] Hernandez-Molina G, Avila-Casado C, Nunez-Alvarez C, et al. Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjgren's syndrome in patients with systemic autoimmune diseases in the clinical setting[J]. Rheumatology (Oxford), 2015,54(3):441-448.
[16] Takagi Y, Sumi M, Nakamura H, et al. Ultrasonography as an additional item in the American College of Rheumatology classification of Sjgren's syndrome[J]. Rheumatology (Oxford),2014,53(11):1977-1983.
[17] Ma＇slińska M, Przygodzka M, Kwiatkowska B,et al. Sjgren's syndrome: still not fully understood disease[J]. Rheumatol Int, 2015,35(2):233-241.
[18] Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol,2015,67(7):1688-1699.
[19] Gossec L, Smolen JS. Treatment of psoriatic arthritis: management recommendations[J]. Clin Exp Rheumatol,2015,33(5 Suppl 93):S73-S77.
[20] Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update[J]. Ann Rheum Dis,2015 Dec 7.
[21] Colebatch-Bourn AN, Conaghan PG, Arden NK,et al. Raising the quality of rheumatology management recommendations: lessons from the EULAR process 10 years after provision of standard operating procedures[J]. Rheumatology (Oxford),2015,54(8):1392-1396.
[22] Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2015,74(10):1789-1798.
[23] Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative[J]. Ann Rheum Dis, 2015,74(10):1799-1807.
[24] Kerola AM, Kauppi MJ, Nieminen T, et al. Psychiatric and cardiovascular comorbidities as causes of long-term work disability among individuals with recent-onset rheumatoid arthritis[J]. Scand J Rheumatol,2015,44(2):87-92.
[25] Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis[J]. Ann Rheum Dis,2015,74(6):954-962.

2015年风湿免疫病主要进展

Major clinical progress of rheumatic disease in 2015

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张娜娜, 崔轶霞, 邹琳. 类风湿关节炎患者骨密度与维生素D相关性研究进展[J]. 临床荟萃, 2024, 39(1): 92-96.
[2]	左腾, 王俊祥. 血清阴性类风湿关节炎发病机制的研究进展[J]. 临床荟萃, 2023, 38(8): 753-756.
[3]	孙佳宁, 崔轶霞. 类风湿关节炎与抑郁症共病的研究进展[J]. 临床荟萃, 2023, 38(7): 663-667.
[4]	沈雪娇, 李燕, 王挺, 王媛. 痛风性关节炎血管内皮功能及其与血尿酸水平的相关性[J]. 临床荟萃, 2023, 38(3): 241-244.
[5]	邹琳, 崔轶霞, 张娜娜, 陈思荣. 类风湿关节炎合并骨质疏松症发病机制和相关治疗药物对骨质疏松症影响的研究进展[J]. 临床荟萃, 2023, 38(3): 279-284.
[6]	张月月, 谢美芳, 孙艮. 类风湿关节炎合并T-细胞大颗粒淋巴细胞白血病1例及文献复习[J]. 临床荟萃, 2022, 37(8): 728-732.
[7]	林长艺, 宋明辉, 吴培埕. 诊断年龄对风湿性多肌痛临床特征的影响: 68例患者的单中心回顾性队列研究[J]. 临床荟萃, 2022, 37(7): 612-615.
[8]	胡芳芳, 钟世玲, 狄亚珍, 吴菱. 幼年特发性关节炎患儿血管内皮功能的系统评价和meta分析[J]. 临床荟萃, 2022, 37(3): 204-210.
[9]	林长艺, 宋明辉, 吴培埕. 缓解性血清阴性对称性滑膜炎伴凹陷性水肿综合征与血清阴性类风湿性关节炎患者临床和实验室特征比较[J]. 临床荟萃, 2022, 37(3): 262-265.
[10]	杨瑞, 刘宇宏. 类风湿关节炎患者血脂水平与心血管疾病风险相关研究进展[J]. 临床荟萃, 2022, 37(1): 92-96.
[11]	李惠婷, 孟景红, 顾光, 陈海英, 王俊祥. 强直性脊柱炎合并髋关节受累的临床特点[J]. 临床荟萃, 2021, 36(6): 500-503.
[12]	刘子奕, 王吉波. 类风湿关节炎合并恶性肿瘤患者的临床特征及相关因素分析[J]. 临床荟萃, 2021, 36(3): 246-250.
[13]	吕怡萱, 卢展飞, 孙念哲, 李福翰, 刘蓉. 双能CT和超声诊断痛风效能的系统评价[J]. 临床荟萃, 2021, 36(1): 5-7.
[14]	何欣, 黄玉琴, 青玉凤, 张全波. 类风湿关节炎相关性肺间质病变治疗进展[J]. 临床荟萃, 2021, 36(1): 75-79.
[15]	孙文静1，戴世鹏1，顾庆2，田苗苗1，尚海霞1. MRI显微线圈成像与类风湿关节炎抗CCP抗体及RF水平的关系[J]. 临床荟萃, 2020, 35(5): 449-452.